Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on September 23, 2015. The report details a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The Board of Directors increased its size from nine to ten members. David R. Walt, Ph.D., was appointed as a new independent director, effective immediately. Dr. Walt will serve as a Class II director with a term expiring at the 2016 Annual Meeting of Stockholders.
Guidance, Outlook, and Management Commentary
There is no financial guidance or outlook provided in this filing. Management commentary is limited to the appointment details:
- Committee Assignments: Dr. Walt will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
- Compensation: Dr. Walt will receive standard non-employee director compensation, including a one-time nonqualified stock option to purchase 22,000 shares of common stock.
- Option Terms: The option has an exercise price of $4.80 per share (equal to the closing price on the grant date) and vests in equal annual installments over three years.
- Indemnification: Dr. Walt will enter into an indemnification agreement covering expenses, judgments, fines, and settlement amounts arising from his service.
Investor Verification Checklist
- Verify the independence status of Dr. Walt under Nasdaq rules and Rule 10A-3.
- Confirm the vesting schedule and exercise price of the 22,000 share stock option grant.
- Review the impact of the Board size increase on quorum requirements and committee composition.
- Check for any potential conflicts of interest given Dr. Walt's roles at Illumina, Inc., Quanterix Corporation, and Ultivue, Inc.